AI model aims to predict which patients with Nearsightedness-Related eye damage will respond to standard therapy
NCT ID NCT07402629
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 110 people with myopic choroidal neovascularization (mCNV), a complication of severe nearsightedness that can cause vision loss. Researchers will use deep learning to analyze eye scan images and build a model that predicts how well patients respond to anti-VEGF injections over two years. The goal is to personalize treatment and reduce the risk of recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a tool that helps doctors personalize anti-VEGF treatment for mCNV, potentially reducing recurrences and preserving vision.
What could go wrong
This is an observational study that does not test a new treatment. The prediction model may not be accurate enough for routine use, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIC CHOROIDAL NEOVASCULARIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••